Trial Profile
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Follicular lymphoma; Lymphoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd; Eisai Inc
- 27 Feb 2024 Status changed from active, no longer recruiting to completed.
- 25 Jan 2024 This trial has been completed in Netherlands (Global end date: 21 Dec 2023).
- 05 Oct 2023 Planned End Date changed from 30 Jun 2023 to 29 Dec 2023.